Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. on October 27, 2016. The filing reports the completion of an asset purchase agreement on October 27, 2016, involving the sale of certain Latin America assets to Invekra, S.A.P.I de C.V., an affiliate of Laboratorios Sanfer S.A. de C.V.
Key Financial Metrics
The filing details a specific transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow for a reporting period.
- Total Purchase Price: $22 million.
- Cash at Closing: $18 million.
- Escrow Amount: $1.5 million (held until delivery of equipment and technology).
- Deferred Consideration: $2.5 million payable in Mexican currency over ten years (calculated as 3% of net sales of certain products in Latin America, excluding Mexico).
- Potential Penalty Liability: Up to $2 million (one-time payment) if the company fails to supply products for a consecutive six-month period during the two-year transition.
Material Changes
The company divested specific assets related to Mexico, the Caribbean, and South America, excluding dermatology products in Brazil. Assets sold include patents, patent applications, trademarks, and manufacturing equipment. The company retains the obligation to supply Microcyn products to partners More Pharma Corporation and Grimann S.A. de C.V. for a two-year transition period.
Outlook, Risks, and Contingencies
Contingencies and Risks:
- Currency Fluctuation: The $2.5 million deferred payment is in Mexican currency; the actual USD value received may vary.
- Supply Penalty: Failure to supply products for six consecutive months triggers a $2 million penalty, which decreases by 12.5% each quarter of the two-year term.
- Default Rights: The company retains an option to recover health registrations in Mexico if Invekra defaults.
- Forward-Looking Statements: The filing includes standard disclaimers that future results may differ materially from expectations due to risks outlined in the company's Form 10-K.
Investor Verification Checklist
- Verify the exact scope of assets excluded from the sale (specifically dermatology products in Brazil).
- Confirm the current status of the $1.5 million escrow and conditions for its release.
- Monitor the company's ability to meet the two-year supply obligations to avoid the $2 million penalty.
- Review the attached Exhibit 10.1 (Asset Purchase Agreement) for detailed representations and warranties.
- Assess the impact of Mexican currency fluctuations on the $2.5 million deferred consideration.